Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europ…
$173.49+2.97%
报价 2026-11-06
市值
$11.09B
EV
$9.82B
PE (TTM)
233.1x
预期 PE (FY2026)
83.7x
52 周区间距高点 -10.8%
$102.87$194.57
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.3x | 2.04 → 2.66（1.3x） | 65.3 |
| FY+32028-12 | 1.5x | 2.04 → 3.42（1.7x） | 50.7 |
毛利率 51% · TTM 收入 $806M · 基数 EPS 2.04（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RGENRepligen Corporation | $11.09B | +3.0% | +15.8% | 53.1% | 233.1x | 56.2x | 87.9x | |
| CRLCharles River Laboratories International, Inc. | $16.17B | +7.8% | -2.2% | 36.2% | – | 91.3x | 46.6x | |
| BAXBaxter International Inc. | $13.34B | +0.5% | +5.8% | 33.4% | – | 25.2x | 13.3x | |
| DVADaVita Inc. | $12.04B | -1.8% | +4.8% | 30.9% | 17.5x | 9.3x | 11.8x | |
| AVTRAvantor, Inc. | $10.48B | +2.2% | +2.2% | 31.5% | 30.9x | 15.1x | 23.9x | |
| BIOBio-Rad Laboratories, Inc. | $10.25B | +3.4% | +0.1% | 51.9% | 9.4x | 9.6x | 27.2x | |
| GMEDGlobus Medical, Inc. | $9.54B | -12.8% | +9.9% | 67.4% | 21.9x | 13.9x | 16.5x | |
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| STVNStevanato Group S.p.A. | $3.71B | +2.7% | +8.3% | 29.1% | 23.9x | 12.0x | – | |
| 同行中位数 | – | – | +5.3% | 32.4% | 21.9x | 13.0x | 23.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $204.1M | $194.3M | $197.9M | $188.8M | $182.4M | $169.2M | $167.5M | $154.9M |
| Gross Margin | 53.1% | 50.7% | 47.2% | 53.2% | 50% | 53.6% | 23.2% | 50% |
| Operating Margin | 5.8% | 9.3% | 9.4% | 8.9% | 7.6% | 3.9% | -21.8% | -5.1% |
| Net Income | $5M | $8.3M | $13.3M | $14.9M | $14.9M | $5.8M | $-33.9M | $-654,000 |
| Diluted EPS | 0.09 | 0.15 | 0.23 | 0.26 | 0.26 | 0.1 | -0.6 | 0.32 |
| Operating Cash Flow | $32.8M | $28.3M | $25.7M | $48.1M | $28.6M | $15M | $39.2M | $49.3M |